Friday, April 20, 2007

Erythropoiesis-stimulating agents (ESAs), Aranesp (darbepoietin alfa) and Eprex (epoetin alfa)

Health Canada:

The manufacturers of the erythropoiesis-stimulating agents (ESAs), in consultation with Health Canada, would like to inform you of updated safety information and pending label changes based on completed or ongoing clinical studies regarding treatment with ESAs. Two such ESAs, Aranesp® and EPREX, are marketed in Canada.
For Health Professionals
For the Public

1 comment:

Anonymous said...

My haemotologist started EPREX 20,000 to treat my anemia. I am deeply anxious and worried when I found out that the drug has expired on August 2005. What are the possible side effects and risks. I had two injections weekly.